NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. The development stage of NeuClone’s eight publicly disclosed biosimilar products are outlined below.
ORIGINATOR
Stelara®
Ustekinumab
Herceptin®
Trastuzumab
Perjeta®
Pertuzumab
Prolia®/Xgeva®
Denosumab
Keytruda®
Pembrolizumab
Synagis®
Palivizumab
Opdivo®
Nivolumab
Humira®
Adalimumab
EARLY PRECLINICAL
LATE PRECLINICAL
PROCESS SCALE-UP
PHASE I
PHASE III
12 other products in development.
Herceptin
Trastuzumab
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2018
Stelara
Ustekinumab
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2019
Prolia/XGEVA
Denosumab
Early Preclinical
Late Preclinical
Process Scale-up
Synagis
Palivizumab
Early Preclinical
Late Preclinical
Process Scale-up
Perjeta
Pertuzumab
Early Preclinical
Late Preclinical
Process Scale-up
Opdivo
Nivolumab
Early Preclinical
Late Preclinical
Process Scale-up
Keytruda
Pembrolizumab
Early Preclinical
Late Preclinical
Process Scale-up
Humira
Adalimumab
Early Preclinical
Late Preclinical
